Gregory S. Friedrichs
Research Subjects
Gregory S. Friedrichs has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Benedict R. Lucchesi
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan
2 shared publicationsHai-Ming Tang
Novartis Biomedical Research, East Hanover, NJ, USA
2 shared publicationsA. Greiter-Wilke
Roche Innovation Center Basel, Grenzacherstr. 124, CH 4070 Basel, Switzerland
1 shared publication- Alan P. Brown
Novartis Biomedical Research
1 shared publication - Axel Vicart
Novartis BioMedical Research, Postfach, 4002 Basel, Switzerland
1 shared publication B.H. Morimoto
Alto Neuroscience, Inc. 369 S San Antonio Rd, Los Altos CA 94022, USA
1 shared publication
Latest Publications
- 26 October 2026
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
Characterization of a guinea pig model to evaluate cardiovascular toxicity risk for targeted protein degraders - Insights and lessons learned
Targeted protein degradation is an active area of pharmaceutical research and development with the promise to increase the potential number of druggable targets across numerous therapeutic areas. One challenge in their current development has been unexpected cardiovascular findings that have been reported during clinical trials with some degraders, primarily delayed ventricular repolarization manifested as longer corrected QT (QTc) intervals and potential for increased arrhythmic risk. The objective of this study was to investigate whether guinea pigs might be a suitable small animal model to characterize potential cardiovascular effects earlier in degrader development in alignment with 3R principles. The pharmacokinetics and cardiovascular effects were measured in naïve guinea pigs using 4 distinct degraders previously tested in non-human primates. We found exposures were broadly lower in guinea pigs than non-human primates, and dose-limiting toxicity was observed with some degraders after increasing the dose (mg/kg) in guinea pigs to account for the lower exposures. No consistent CV changes were observed across all 4 degraders, which was not translatable to the QTc interval prolongation observed in non-human primates administered the same degraders. Lastly, an anesthetized guinea pig model was investigated to evaluate acute cardiovascular changes at elevated in vivo exposures beyond those achieved in the conscious preparations. However, no consistent changes were observed in QTc intervals. In this context of this preliminary investigation of 4 degraders, the guinea pig model was not a suitable option for evaluating cardiovascular liabilities.
- 26 October 2026
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
Characterization of a guinea pig model to evaluate cardiovascular toxicity risk for targeted protein degraders - Insights and lessons learned
Targeted protein degradation is an active area of pharmaceutical research and development with the promise to increase the potential number of druggable targets across numerous therapeutic areas. One challenge in their current development has been unexpected cardiovascular findings that have been reported during clinical trials with some degraders, primarily delayed ventricular repolarization manifested as longer corrected QT (QTc) intervals and potential for increased arrhythmic risk. The objective of this study was to investigate whether guinea pigs might be a suitable small animal model to characterize potential cardiovascular effects earlier in degrader development in alignment with 3R principles. The pharmacokinetics and cardiovascular effects were measured in naïve guinea pigs using 4 distinct degraders previously tested in non-human primates. We found exposures were broadly lower in guinea pigs than non-human primates, and dose-limiting toxicity was observed with some degraders after increasing the dose (mg/kg) in guinea pigs to account for the lower exposures. No consistent CV changes were observed across all 4 degraders, which was not translatable to the QTc interval prolongation observed in non-human primates administered the same degraders. Lastly, an anesthetized guinea pig model was investigated to evaluate acute cardiovascular changes at elevated in vivo exposures beyond those achieved in the conscious preparations. However, no consistent changes were observed in QTc intervals. In this context of this preliminary investigation of 4 degraders, the guinea pig model was not a suitable option for evaluating cardiovascular liabilities.
- 8 February 2024
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 43 (3) , 231-242
Electrophysiological Changes in the Rabbit Ventricular Wedge and Human-Induced Pluripotent Stem-Cell Derived (IPSC) Cardiomyocytes Translate to Severe Arrhythmia Observed in a Canine Toxicology Study, Not Predicted by Standard In Vitro Ion Channel Assays
During drug discovery, small molecules are typically assayed in vitro for secondary pharmacology effects, which include ion channels relevant to cardiac electrophysiology. Compound A was an irreversible inhibitor of myeloperoxidase investigated for the treatment of peripheral artery disease. Oral doses in dogs at ≥5 mg/kg resulted in cardiac arrhythmias in a dose-dependent manner (at Cmax, free ≥1.53 μM) that progressed in severity with time. Nevertheless, a panel of 13 different cardiac ion channel (K, Na, and Ca) assays, including hERG, failed to identify pharmacologic risks of the molecule. Compound A and a related Compound B were evaluated for electrophysiological effects in the isolated rabbit ventricular wedge assay. Compounds A and B prolonged QT and Tp-e intervals at ≥1 and ≥.3 μM, respectively, and both prolonged QRS at ≥5 μM. Compound A produced early after depolarizations and premature ventricular complexes at ≥5 μM. These data indicate both compounds may be modulating hERG (Ikr) and Nav1.5 ion channels. In human IPSC cardiomyocytes, Compounds A and B prolonged field potential duration at ≥3 μM and induced cellular dysrhythmia at ≥10 and ≥3 μM, respectively. In a rat toxicology study, heart tissue: plasma concentration ratios for Compound A were ≥19X at 24 hours post-dose, indicating significant tissue distribution. In conclusion, in vitro ion channel assays may not always identify cardiovascular electrophysiological risks observed in vivo, which can be affected by tissue drug distribution. Risk for arrhythmia may increase with a “trappable” ion channel inhibitor, particularly if cardiac tissue drug levels achieve a critical threshold for pharmacologic effects.
- 8 February 2024
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 43 (3) , 231-242
Electrophysiological Changes in the Rabbit Ventricular Wedge and Human-Induced Pluripotent Stem-Cell Derived (IPSC) Cardiomyocytes Translate to Severe Arrhythmia Observed in a Canine Toxicology Study, Not Predicted by Standard In Vitro Ion Channel Assays
During drug discovery, small molecules are typically assayed in vitro for secondary pharmacology effects, which include ion channels relevant to cardiac electrophysiology. Compound A was an irreversible inhibitor of myeloperoxidase investigated for the treatment of peripheral artery disease. Oral doses in dogs at ≥5 mg/kg resulted in cardiac arrhythmias in a dose-dependent manner (at Cmax, free ≥1.53 μM) that progressed in severity with time. Nevertheless, a panel of 13 different cardiac ion channel (K, Na, and Ca) assays, including hERG, failed to identify pharmacologic risks of the molecule. Compound A and a related Compound B were evaluated for electrophysiological effects in the isolated rabbit ventricular wedge assay. Compounds A and B prolonged QT and Tp-e intervals at ≥1 and ≥.3 μM, respectively, and both prolonged QRS at ≥5 μM. Compound A produced early after depolarizations and premature ventricular complexes at ≥5 μM. These data indicate both compounds may be modulating hERG (Ikr) and Nav1.5 ion channels. In human IPSC cardiomyocytes, Compounds A and B prolonged field potential duration at ≥3 μM and induced cellular dysrhythmia at ≥10 and ≥3 μM, respectively. In a rat toxicology study, heart tissue: plasma concentration ratios for Compound A were ≥19X at 24 hours post-dose, indicating significant tissue distribution. In conclusion, in vitro ion channel assays may not always identify cardiovascular electrophysiological risks observed in vivo, which can be affected by tissue drug distribution. Risk for arrhythmia may increase with a “trappable” ion channel inhibitor, particularly if cardiac tissue drug levels achieve a critical threshold for pharmacologic effects.
- 13 August 2020
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 39 (6) , 542-546
Respiratory Rates Derived From Arterial Blood Pressure Waveforms in Telemetered Dogs
The objective of this study was to extract low frequency respiratory “artifacts” from a standard arterial blood pressure (ABP) waveform to simultaneously derive reliable breathing rates (BR). Arterial blood pressure derived BR values were characterized against respiratory rates simultaneously obtained from the Respiratory Inductive Plethysmography (RIP) system (EMKA). Reference compounds were introduced to evaluate responsiveness of the derived measures to respiratory depressants and stimulants. Male beagle dogs (n = 3) were instrumented with minimally invasive telemetry devices for measurements of ABP and heart rate. The RIP system was utilized simultaneously to collect respiratory rate, tidal volume, and minute volume of each animal following pharmacological challenges. Early results revealed the derived BR’s from ABP waveforms did not correlate well with those measured from the RIP system. Post study X-ray visualization revealed suboptimal catheter positioning, causing poor concordance of BR tallied from the ABP waveforms. Follow-up evaluations were conducted using additional animals instrumented with the ABP catheter tip placement advanced proximal to the thoracic diaphragm. Preliminary data from this subset of animals significantly improved the correlation of BR derived from ABP and respiratory rates recorded by the RIP. This proof of concept investigation was intended to evaluate an algorithm designed to extract additional data from routine cardiac waveforms. We clearly demonstrated that with optimal blood pressure catheter placement and acquisition algorithm, a reliable breathing rate can also be extracted from safety studies without the need for additional studies/animals to capture those respiratory end points.
- 13 August 2020
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 39 (6) , 542-546
Respiratory Rates Derived From Arterial Blood Pressure Waveforms in Telemetered Dogs
The objective of this study was to extract low frequency respiratory “artifacts” from a standard arterial blood pressure (ABP) waveform to simultaneously derive reliable breathing rates (BR). Arterial blood pressure derived BR values were characterized against respiratory rates simultaneously obtained from the Respiratory Inductive Plethysmography (RIP) system (EMKA). Reference compounds were introduced to evaluate responsiveness of the derived measures to respiratory depressants and stimulants. Male beagle dogs (n = 3) were instrumented with minimally invasive telemetry devices for measurements of ABP and heart rate. The RIP system was utilized simultaneously to collect respiratory rate, tidal volume, and minute volume of each animal following pharmacological challenges. Early results revealed the derived BR’s from ABP waveforms did not correlate well with those measured from the RIP system. Post study X-ray visualization revealed suboptimal catheter positioning, causing poor concordance of BR tallied from the ABP waveforms. Follow-up evaluations were conducted using additional animals instrumented with the ABP catheter tip placement advanced proximal to the thoracic diaphragm. Preliminary data from this subset of animals significantly improved the correlation of BR derived from ABP and respiratory rates recorded by the RIP. This proof of concept investigation was intended to evaluate an algorithm designed to extract additional data from routine cardiac waveforms. We clearly demonstrated that with optimal blood pressure catheter placement and acquisition algorithm, a reliable breathing rate can also be extracted from safety studies without the need for additional studies/animals to capture those respiratory end points.
- 14 May 2020
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 39 (4) , 274-293
An Industry Survey With Focus on Cardiovascular Safety Pharmacology Study Design and Data Interpretation
Introduction: The Safety Pharmacology Society (SPS) conducted a membership survey to examine industry practices related mainly to cardiovascular (CV) safety pharmacology (SP). Methods: Questions addressed nonclinical study design, data analysis methods, drug-induced effects, and conventional and novel CV assays. Results: The most frequent therapeutic area targeted by drugs developed by the companies/institutions that employ survey responders was oncology. The most frequently observed drug-mediated effects included an increased heart rate, increased arterial blood pressure, hERG (IKr) block, decreased arterial blood pressure, decreased heart rate, QTc prolongation, and changes in body temperature. Broadly implemented study practices included Latin square crossover study design with n = 4 for nonrodent CV studies, statistical analysis of data (eg, analysis of variance), use of arrhythmia detection software, and the inclusion of data from all study animals when integrating SP studies into toxicology studies. Most responders frequently used individual animal housing conditions. Responders commonly evaluated drug effects on multiple ion channels, but in silico modeling methods were used much less frequently. Most responders rarely measured the J-Tpeak interval in CV studies. Uncertainties relative to Standard for Exchange of Nonclinical Data applications for data derived from CV SP studies were common. Although available, the use of human induced pluripotent stem cell cardiomyocytes remains rare. The respiratory SP study was rarely involved with identifying drug-induced functional issues. Responders indicated that the study-derived no observed effect level was more frequently determined than the no observed adverse effect level in CV SP studies; however, a large proportion of survey responders used neither.
- 14 May 2020
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 39 (4) , 274-293
An Industry Survey With Focus on Cardiovascular Safety Pharmacology Study Design and Data Interpretation
Introduction: The Safety Pharmacology Society (SPS) conducted a membership survey to examine industry practices related mainly to cardiovascular (CV) safety pharmacology (SP). Methods: Questions addressed nonclinical study design, data analysis methods, drug-induced effects, and conventional and novel CV assays. Results: The most frequent therapeutic area targeted by drugs developed by the companies/institutions that employ survey responders was oncology. The most frequently observed drug-mediated effects included an increased heart rate, increased arterial blood pressure, hERG (IKr) block, decreased arterial blood pressure, decreased heart rate, QTc prolongation, and changes in body temperature. Broadly implemented study practices included Latin square crossover study design with n = 4 for nonrodent CV studies, statistical analysis of data (eg, analysis of variance), use of arrhythmia detection software, and the inclusion of data from all study animals when integrating SP studies into toxicology studies. Most responders frequently used individual animal housing conditions. Responders commonly evaluated drug effects on multiple ion channels, but in silico modeling methods were used much less frequently. Most responders rarely measured the J-Tpeak interval in CV studies. Uncertainties relative to Standard for Exchange of Nonclinical Data applications for data derived from CV SP studies were common. Although available, the use of human induced pluripotent stem cell cardiomyocytes remains rare. The respiratory SP study was rarely involved with identifying drug-induced functional issues. Responders indicated that the study-derived no observed effect level was more frequently determined than the no observed adverse effect level in CV SP studies; however, a large proportion of survey responders used neither.
- 1 September 1996
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 1 (3) , 219-228
Reduction of Myocardial Necrosis after Glycosaminoglycan Administration: Effects of a Single Intravenous Administration of Heparin or N-Acetylheparin 2 Hours before Regional Ischemia and Reperfusion
We determined if a single administration of heparin or nonanticoagulant N-acetylheparin could reduce myocardial injury resulting from a 90-minute occlusion of the left circumflex coronary artery (LCX) and 6 hours of reperfusion in the anesthetized canine. Heparin (2 mg/kg), N-acetylheparin (2 mg/kg), or vehicle, 0.9% sodium chloride (control), was administered intravenously to separate groups of animals 2 hours before LCX occlusion. To ensure parity of LCX ischemia, only animals with ischemic zone regional blood flow < 0.16 mL/min/g tissue were included in the final analysis. Hemodynamics did not differ among the three study groups. Infarct size as a percentage of the left ventricular area at risk was obtained for each group. Myocardial infarct size was 43.0 ± 3.9% in the vehicle, 28.8 ± 5.8% in the heparin (P < .05 vs vehicle) and 24.7 ± 4.6% (P < .05 vs vehicle) in the N-acetylheparin-treated animals. Pretreatment with heparin or its nonanticoagulant derivative, N-acetylheparin, provides significant protection to the regionally ischemic and reperfused canine myocardium independent of either plasma glycosaminoglycan concentration or alterations in the coagulation system.
- 1 September 1996
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 1 (3) , 219-228
Reduction of Myocardial Necrosis after Glycosaminoglycan Administration: Effects of a Single Intravenous Administration of Heparin or N-Acetylheparin 2 Hours before Regional Ischemia and Reperfusion
We determined if a single administration of heparin or nonanticoagulant N-acetylheparin could reduce myocardial injury resulting from a 90-minute occlusion of the left circumflex coronary artery (LCX) and 6 hours of reperfusion in the anesthetized canine. Heparin (2 mg/kg), N-acetylheparin (2 mg/kg), or vehicle, 0.9% sodium chloride (control), was administered intravenously to separate groups of animals 2 hours before LCX occlusion. To ensure parity of LCX ischemia, only animals with ischemic zone regional blood flow < 0.16 mL/min/g tissue were included in the final analysis. Hemodynamics did not differ among the three study groups. Infarct size as a percentage of the left ventricular area at risk was obtained for each group. Myocardial infarct size was 43.0 ± 3.9% in the vehicle, 28.8 ± 5.8% in the heparin (P < .05 vs vehicle) and 24.7 ± 4.6% (P < .05 vs vehicle) in the N-acetylheparin-treated animals. Pretreatment with heparin or its nonanticoagulant derivative, N-acetylheparin, provides significant protection to the regionally ischemic and reperfused canine myocardium independent of either plasma glycosaminoglycan concentration or alterations in the coagulation system.
- 1 April 1994
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 28 (4) , 437-444
The complement system in myocardial ischaemia/reperfusion injury
Kenneth S Kilgore, Gregory S Friedrichs, Jonathon W Homeister, Benedict R Lucchesi; The complement system in myocardial ischaemia/reperfusion injury, Cardiovas
- 1 April 1994
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 28 (4) , 437-444
The complement system in myocardial ischaemia/reperfusion injury
Kenneth S Kilgore, Gregory S Friedrichs, Jonathon W Homeister, Benedict R Lucchesi; The complement system in myocardial ischaemia/reperfusion injury, Cardiovas
- Open Access
- 1 January 1994
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 23 (1) , 120-126
Antiarrhythmic Agent, MS-551, Protects Against Pinacidil + Hypoxia-Induced Ventricular Fibrillation in Langendorff-Perfused Rabbit Isolated Heart
We studied the electrophysiologic and anti-fibrillatory effects of the class III agent MS-551 in a rabbit isolated heart model in which ventricular fibrillation (VF) occurs reproducibly under conditions of hyp-oxia/reoxygenation in the presence of the ATP-dependent potassium channel opener, pinacidil. Ten minutes after MS-551 or vehicle administration, addition of pinacidil (1.25 μM) to the buffer was followed by a 12-min hypoxic period and 40-min reoxygenation. At a low concentration of MS-551 (1.0 μM), VF occurred in 5 of 6 hearts, the same incidence as in the control group (5 of 6). In contrast 0 of 6 hearts treated with 15 μM MS-551 developed VF (p < 0.05 vs. vehicle). Ventricular effective refractory period (VERP) was determined in a separate group of isolated hearts (n = 13). Pinacidil alone, during normoxic perfusion, decreased VERP 48 ± 11% (p < 0.05) 15 min after exposure. Five minutes of hypoxia alone also decreased VERP (57 ± 8%, p < 0.05). Under normoxic conditions, MS-551 increased ERP 31 ± 10% (p < 0.05 vs. baseline). VERP prolongation by MS-551 was reduced in the presence of pinacidil but remained 22 ± 6% (p < 0.05) above baseline. The results suggest that VERP shortening owing to pinacidil mediated ATP-dependent K+ channel opening is associated with development of VF in isolated heart. MS-551 attenuates the pinacidil-mediated decrease in VERP and prevents pinacidil + hypoxia-reoxygenation-induced VF. Because pinacidil and hypoxia open myocardial KATP channels, putatively decreasing VERP, MS-551 may exert its antifibrillatory effect through partial blockade of K+ATP channels
- 1 January 1994
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 23 (1) , 120-126
Open AccessAntiarrhythmic Agent, MS-551, Protects Against Pinacidil + Hypoxia-Induced Ventricular Fibrillation in Langendorff-Perfused Rabbit Isolated Heart
We studied the electrophysiologic and anti-fibrillatory effects of the class III agent MS-551 in a rabbit isolated heart model in which ventricular fibrillation (VF) occurs reproducibly under conditions of hyp-oxia/reoxygenation in the presence of the ATP-dependent potassium channel opener, pinacidil. Ten minutes after MS-551 or vehicle administration, addition of pinacidil (1.25 μM) to the buffer was followed by a 12-min hypoxic period and 40-min reoxygenation. At a low concentration of MS-551 (1.0 μM), VF occurred in 5 of 6 hearts, the same incidence as in the control group (5 of 6). In contrast 0 of 6 hearts treated with 15 μM MS-551 developed VF (p < 0.05 vs. vehicle). Ventricular effective refractory period (VERP) was determined in a separate group of isolated hearts (n = 13). Pinacidil alone, during normoxic perfusion, decreased VERP 48 ± 11% (p < 0.05) 15 min after exposure. Five minutes of hypoxia alone also decreased VERP (57 ± 8%, p < 0.05). Under normoxic conditions, MS-551 increased ERP 31 ± 10% (p < 0.05 vs. baseline). VERP prolongation by MS-551 was reduced in the presence of pinacidil but remained 22 ± 6% (p < 0.05) above baseline. The results suggest that VERP shortening owing to pinacidil mediated ATP-dependent K+ channel opening is associated with development of VF in isolated heart. MS-551 attenuates the pinacidil-mediated decrease in VERP and prevents pinacidil + hypoxia-reoxygenation-induced VF. Because pinacidil and hypoxia open myocardial KATP channels, putatively decreasing VERP, MS-551 may exert its antifibrillatory effect through partial blockade of K+ATP channels